Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2016 (2016), Article ID 3743420, 8 pages
http://dx.doi.org/10.1155/2016/3743420
Review Article

Neoadjuvant Therapy in Differentiated Thyroid Cancer

1Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, USA
2Department of Hematology-Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Received 20 December 2015; Revised 10 August 2016; Accepted 29 August 2016

Academic Editor: S. Curley

Copyright © 2016 Rajan P. Dang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. R. Posner, “Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy,” The Oncologist, vol. 10, supplement 3, pp. 11–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Licitra and J. B. Vermorken, “Is there still a role for neoadjuvant chemotherapy in head and neck cancer?” Annals of Oncology, vol. 15, no. 1, pp. 7–11, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Ark, S. Zemo, D. Nolen, F. C. Holsinger, and R. S. Weber, “Management of locally invasive well-differentiated thyroid cancer,” Surgical Oncology Clinics of North America, vol. 17, no. 1, pp. 145–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. G. Silverberg, R. V. Hutter, and F. W. Foote Jr., “Fatal carcinoma of the thyroid: histology, metastases, and causes of death,” Cancer, vol. 25, no. 4, pp. 792–802, 1970. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Gottlieb, C. S. Hill Jr., M. L. Ibanez, and R. L. Clark, “Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients,” Cancer, vol. 30, no. 3, pp. 848–853, 1972. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Gottlieb and C. S. Hill Jr., “Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients,” The New England Journal of Medicine, vol. 290, no. 4, pp. 193–197, 1974. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Matuszczyk, S. Petersenn, A. Bockisch et al., “Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium,” Hormone and Metabolic Research, vol. 40, no. 3, pp. 210–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. D. Williams, R. Birch, and L. H. Einhorn, “Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial,” Cancer Treatment Reports, vol. 70, no. 3, pp. 405–407, 1986. View at Google Scholar · View at Scopus
  9. K. Shimaoka, D. A. Schoenfeld, W. D. DeWys, R. H. Creech, and R. DeConti, “A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma,” Cancer, vol. 56, no. 9, pp. 2155–2160, 1985. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Matuszczyk, S. Petersenn, W. Voigt et al., “Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium,” Hormone and Metabolic Research, vol. 42, no. 1, pp. 61–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Besic, M. Auersperg, B. Gazic, M. Dremelj, and I. Zagar, “Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or hürthle cell thyroid carcinoma: a phase 2 study,” Thyroid, vol. 22, no. 2, pp. 131–137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Besic, M. Auersperg, M. Dremelj, B. Vidergar-Kralj, and B. Gazic, “Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma,” Thyroid, vol. 23, no. 2, pp. 178–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Ito, T. Higashiyama, M. Hirokawa et al., “Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component,” Endocrine Journal, vol. 59, no. 9, pp. 839–844, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Hartl, S. Zago, S. Leboulleux et al., “Resection margins and prognosis in locally invasive thyroid cancer,” Head and Neck, vol. 36, no. 7, pp. 1034–1038, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. S. Brose, C. M. Nutting, B. Jarzab et al., “Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial,” The Lancet, vol. 384, no. 9940, pp. 319–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Marotta, V. Ramundo, L. Camera et al., “Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET,” Clinical Endocrinology, vol. 78, no. 5, pp. 760–767, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C. de la Fouchardiere, M.-H. Massicotte, I. Borget et al., “Sequential TKI treatments for iodine-refractory differentiated thyroid carcinomas,” Journal of Clinical Oncology, vol. 31, supplement 15, abstract S6092, 2013. View at Google Scholar
  18. L. Chen, Y. Shen, Q. Luo, Y. Yu, H. Lu, and R. Zhu, “Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma,” Thyroid, vol. 21, no. 2, pp. 119–124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. E. Cabanillas, S. G. Waguespack, Y. Bronstein et al., “Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2588–2595, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. E. J. Sherman, A. L. Ho, M. G. Fury et al., “Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer,” Journal of Clinical Oncology, vol. 31, supplement 1, abstract 6024, 2013. View at Google Scholar
  21. E. Sherman, A. Ho, M. Fury et al., “A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma,” Journal of Clinical Oncology, vol. 29, supplement, p. A5514, 2012. View at Google Scholar
  22. D. S. Hong, M. E. Cabanillas, J. Wheler et al., “Inhibition of the ras/raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 4, pp. 997–1005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. E. Cabanillas, R. Kurzrock, S. Sherman et al., “Phase I trial of combination sorafenib and tipifarnib: the experience of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) (abstract 5586),” Journal of Clinical Oncology, vol. 28, supplement 15, p. S5586, 2010. View at Google Scholar
  24. “A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT),” in Proceedings of the ASCO Annual Meeting, M. Schlumberger, Ed., Chicago, Ill, USA, 2014.
  25. S. Sherman, B. Jarzab, M. Cabanillas et al., “A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC),” Journal of Clinical Oncology, vol. 29, no. 15, supplement, abstract 5503, 2011, Proceedings of the ASCO Annual Meeting. View at Google Scholar
  26. K. C. Bible, V. J. Suman, J. R. Molina et al., “Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study,” The Lancet Oncology, vol. 11, no. 10, pp. 962–972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. E. Nikiforov and M. N. Nikiforova, “Molecular genetics and diagnosis of thyroid cancer,” Nature Reviews Endocrinology, vol. 7, no. 10, pp. 569–580, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Grande, J. J. Díez, C. Zafon, and J. Capdevila, “Thyroid cancer: molecular aspects and new therapeutic strategies,” Journal of Thyroid Research, vol. 2012, Article ID 847108, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Kumar, V. B. Knick, S. K. Rudolph et al., “Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity,” Molecular Cancer Therapeutics, vol. 6, no. 7, pp. 2012–2021, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. H. I. Hurwitz, A. Dowlati, S. Saini et al., “Phase I trial of pazopanib in patients with advanced cancer,” Clinical Cancer Research, vol. 15, no. 12, pp. 4220–4227, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. S. Brose, J. Smit, J. Capdevila et al., “Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma,” Expert Review of Anticancer Therapy, vol. 12, no. 9, pp. 1137–1147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Capdevila, G. Argiles, V. Rodriguez-Frexinos, I. Nuñez, and J. Tabernero, “New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era,” Discovery medicine, vol. 9, no. 45, pp. 153–162, 2010. View at Google Scholar · View at Scopus
  33. D. C. McFarland and K. J. Misiukiewicz, “Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer,” OncoTargets and Therapy, vol. 7, pp. 1291–1299, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. S. W. Bayles, T. T. Kingdom, and G. W. Carlson, “Management of thyroid carcinoma invading the aerodigestive tract,” The Laryngoscope, vol. 108, no. 9, pp. 1402–1407, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. T. V. McCaffrey, E. J. Bergstralh, and I. D. Hay, “Locally invasive papillary thyroid carcinoma: 1940–1990,” Head and Neck, vol. 16, no. 2, pp. 165–172, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. J. C. McCaffrey, “Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology,” The Laryngoscope, vol. 116, no. 1, pp. 1–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Czaja and T. V. McCaffrey, “The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma,” Archives of Otolaryngology—Head & Neck Surgery, vol. 123, no. 5, pp. 484–490, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Friedman, J. A. Danielzadeh, and D. D. Caldarelli, “Treatment of patients with carcinoma of the thyroid invading the airway,” Archives of Otolaryngology—Head & Neck Surgery, vol. 120, no. 12, pp. 1377–1381, 1994. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Brauckhoff, A. MacHens, P. N. Thanh et al., “Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival,” Surgery, vol. 148, no. 6, pp. 1257–1266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. A. Gaissert, J. Honings, H. C. Grillo et al., “Segmental laryngotracheal and tracheal resection for invasive thyroid carcinoma,” The Annals of Thoracic Surgery, vol. 83, no. 6, pp. 1952–1959, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. T. M. McCarty, J. A. Kuhn, W. L. Williams Jr. et al., “Surgical management of thyroid cancer invading the airway,” Annals of Surgical Oncology, vol. 4, no. 5, pp. 403–408, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Tsukahara, I. Sugitani, and K. Kawabata, “Surgical management of tracheal shaving for papillary thyroid carcinoma with tracheal invasion,” Acta Oto-Laryngologica, vol. 129, no. 12, pp. 1498–1502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. R. J. Robbins, Q. Wan, R. K. Grewal et al., “Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 2, pp. 498–505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Deandreis, A. Al Ghuzlan, S. Leboulleux et al., “Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?” Endocrine-Related Cancer, vol. 18, no. 1, pp. 159–169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. W.-X. Qi, Y.-J. Sun, L.-N. Tang, Z. Shen, and Y. Yao, “Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis,” Critical Reviews in Oncology/Hematology, vol. 89, no. 3, pp. 394–403, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Schlumberger, M. Tahara, L. J. Wirth et al., “Lenvatinib versus placebo in radioiodine-refractory thyroid cancer,” The New England Journal of Medicine, vol. 372, no. 7, pp. 621–630, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. Eisai Co. L. Lenvima Package Insert, 2016.
  48. D. R. Spigel, J. D. Hainsworth, D. A. Yardley et al., “Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 43–48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Goodgame, N. Veeramachaneni, A. Patterson, and R. Govindan, “Tracheo-esophageal fistula with bevacizumab after mediastinal radiation,” Journal of Thoracic Oncology, vol. 3, no. 9, pp. 1080–1081, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Gore, A. Currey, and N. Choong, “Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy,” Journal of Thoracic Oncology, vol. 4, no. 12, pp. 1590–1591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Y. Seiwert, D. J. Haraf, E. E. W. Cohen et al., “Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1732–1741, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. D. P. Blevins, R. Dadu, M. Hu et al., “Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer,” Thyroid, vol. 24, no. 5, pp. 918–922, 2014. View at Publisher · View at Google Scholar · View at Scopus